Project archive

Aloxistatin (E64D) is a cysteine protease inhibitor that has been known for many decades and was originally developed for treating neurodegenerative diseases and muscular dystrophy. In addition, Aloxistatin has shown efficient inhibition of SARS-CoV-2 replication.

Alternative, new-approach methodologies (NAMs) combining human-relevant in-vitro methods and computational (in-silico) approaches hold much promise.

In cooperation with the Hannover Medical School, Fraunhofer ITEM scientists are investigating the safety and efficacy of inhaled booster vaccination with the vector vaccine MVA-SARS-2-ST in a phase-I trial.

Together with several industry partners, Fraunhofer ITEM scientists published novel data on neoepitope biomarkers of type I, III and VI collagen formation or degradation in precision-cut lung slices (PCLS) from patients with Pulmonary fibrosis.

The aim of an exploratory clinical study funded by the German Federal Environment Agency is to determine the respective threshold doses that trigger allergic symptoms in people allergic to ragweed or birch pollen.

The RealWorld4Clinic project consortium develops a medical multi-sensor system (MySentinel) that will enable high-quality collection of real-life cardiorespiratory health data.

The published results suggest a new therapeutic target for neutrophil-mediated secondary tissue injury, such as that seen in acute respiratory distress syndrome.

With the help of a novel nanoparticle transfer system, messenger RNA (mRNA) encoding green fluorescent protein (GFP) can be delivered into human cardiomyocytes.

Researchers use bioinformatics-based prediction of RNA targets in fibrosis to identify novel molecular effectors. In subsequent in-vitro and ex-vivo studies, they investigated their functional impact by means of what is known as siRNA molecules.

The Fraunhofer project FibroPaths® aims to enable rapid and safe development of antifibrotic drugs.